Article
Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.
The Journal of infectious diseases - 1 Feb 2004
Belshe Robert B, Newman Frances K, Tsai Theodore F, Karron Ruth A, Reisinger Keith, Roberton Don, Marshall Helen, Schwartz Richard, King James, Henderson Frederick W, Rodriguez William, Severs Joseph M, Wright Peter F, Keyserling Harry, Weinberg Geoffrey A, Bromberg Kenneth, Loh Richard, Sly Peter, McIntyre Peter, Ziegler John B, Hackell Jill, Deatly Anne, Georgiu Alice, Paschalis Maribel, Wu Shin-Lu, Tatem Joanne M, Murphy Brian, Anderson Edwin
Abstract excerpt
A phase 2 evaluation of live attenuated parainfluenza type 3 (PIV3)-cold passage mutant 45 (cp45) vaccine was conducted in 380 children 6-18 months old; 226 children (59%) were seronegative for PIV3. Of the 226 seronegative children, 114 received PIV3-cp45 vaccine, and 112 received placebo. No significant difference in the occurrence of adverse events (i.e., runny nose, cough, or temperature > or =38 degrees C)...
Topics
- Acute Disease
- Administration, Intranasal
- Antibodies, Viral
- Australia
- Cold Temperature
- Cough
- Double-Blind Method
- Fever